Drug Delivery's Product Risk and Reward
This article was originally published in Start Up
Executive Summary
The great recognition of the drug delivery industry is that technologies don't sell--only drugs do. The result: drug delivery start-ups today must be drug companies, selling their best shot at using their technologies to create highly differentiated drug products. To do so, start-ups are pursuing two different visions. On the one hand are those who try to do as little as possible to the underlying molecule, thereby reducing risk and cost while relying on their system for product differentiation. On the other are those who believe that only important modifications to the molecule, or at least a deep understanding of the biology underlying a specific compound's therapeutic role, permit fundamental improvements in treatment.
You may also be interested in...
Madeira To Reformulate Adults Drugs For Pediatric Use, With First Focus On Statin
Kansas-based specialty pharma sees strong opportunity in 8-to-12-year-old segment with liquid formulations of already approved drugs.
Madeira To Reformulate Adults Drugs For Pediatric Use, With First Focus On Statin
Kansas-based specialty pharma sees strong opportunity in 8-to-12-year-old segment with liquid formulations of already approved drugs.
The Drug Delivery Road Gets Tougher
While making money in drug delivery has always been tougher than its boosters have promised, this year's been ugly in new and disturbing ways. The key lessons of Pfizer's abandonment of inhaled insulin and Impax's patent assault on Endo's Opana are that partners are less reliable; the products need to be medically superior to existing ones, not simply more convenient; and generic companies are making inroads into the main bastion of drug-delivery success -- spec pharma.